Robert Augustin
Birkendorfer Str. 65
Biberach An Der Riss, BW 88400, Germany
Biberach An Der Riss, BW 88400, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Journal: Molecular metabolism
Published: November 12, 2025
Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
Journal: Molecular metabolism
Published: April 11, 2025
A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice.
Journal: Molecular metabolism
Published: December 17, 2024
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Journal: Diabetes, obesity & metabolism
Published: January 24, 2024
Perspectives in weight control in diabetes - Survodutide.
Journal: Diabetes research and clinical practice
Published: April 14, 2023
Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application.
Journal: Molecular metabolism
Published: February 19, 2021
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Journal: Molecular metabolism
Published: July 30, 2020
AmAMP1 from Acropora millepora and damicornin define a family of coral-specific antimicrobial peptides related to the Shk toxins of sea anemones.
Journal: Developmental and comparative immunology
Published: July 02, 2020
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease.
Journal: Peptides
Published: August 28, 2019
Last Updated: 09/26/2026